PE20070701A1 - Terapia contra el cancer con estrogeno - Google Patents
Terapia contra el cancer con estrogenoInfo
- Publication number
- PE20070701A1 PE20070701A1 PE2006001549A PE2006001549A PE20070701A1 PE 20070701 A1 PE20070701 A1 PE 20070701A1 PE 2006001549 A PE2006001549 A PE 2006001549A PE 2006001549 A PE2006001549 A PE 2006001549A PE 20070701 A1 PE20070701 A1 PE 20070701A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- estrogen
- postmenopausic
- paclitaxel
- against cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN METODO DE TRATAMIENTO PARA EL CANCER QUE CONSISTE A) EN IDENTIFICAR UN PACIENTE CON CANCER QUE TIENE UN NIVEL DE ESTROGENO PREMENOPAUSICO EN PLASMA DE 30PG/ML Y POSTMENOPAUSICO; Y B) ADMINISTRAR UN CONJUGADO QUE COMPRENDE a) UN POLIMERO POLI(AMINOACIDO) TAL COMO POLI(ACIDO GLUTAMICO) CONJUGADO A b) UNA DROGA ANTI-CANCER TAL COMO PACLITAXEL, EL CUAL SE ADMINISTRA EN UNA CANTIDAD DE 175 A 250MG/M2 DE EQUIVALENTES DE PACLITAXEL; Y OPCIONALMENTE UNA TERAPIA CON ESTROGENO EN EL CASO DEL PACIENTE QUE TIENE UN NIVEL DE ESTROGENO POSTMENOPAUSICO. DICHO METODO DE TRATAMIENTO SE CARACTERIZA PORQUE EL CANCER PRESENTA CELULAS CANCERIGENAS QUE TIENEN RECEPTORES DE ESTROGENO O EL CANCER SE ORIGINO EN UN TEJIDO U ORGANO QUE TIENE CELULAS QUE POSEEN RECEPTORES DE ESTROGENO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74272505P | 2005-12-06 | 2005-12-06 | |
US81422106P | 2006-06-16 | 2006-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070701A1 true PE20070701A1 (es) | 2007-07-20 |
Family
ID=37891993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001549A PE20070701A1 (es) | 2005-12-06 | 2006-12-05 | Terapia contra el cancer con estrogeno |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070167349A1 (es) |
EP (1) | EP1957065A1 (es) |
JP (1) | JP2009518406A (es) |
KR (1) | KR20080074202A (es) |
CA (1) | CA2630553A1 (es) |
PE (1) | PE20070701A1 (es) |
RU (1) | RU2008127309A (es) |
TW (1) | TWI322010B (es) |
WO (1) | WO2007067498A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014250A1 (en) * | 2008-08-01 | 2010-02-04 | Cell Therapeutics, Inc. | Prediction of cancer therapy based on cathespin b levels |
WO2010014249A1 (en) * | 2008-08-01 | 2010-02-04 | Cell Therapeutics, Inc. | Cancer therapy comprising estrogen inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
GB9120653D0 (en) * | 1991-09-27 | 1991-11-06 | Procter & Gamble | Dispensing agent |
US5731316A (en) * | 1996-01-30 | 1998-03-24 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
CA2250295C (en) * | 1996-03-12 | 2008-12-30 | Pg-Txl Company L.P. | Water soluble paclitaxel prodrugs |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
AU3606700A (en) * | 1999-02-26 | 2000-09-14 | Napro Biotherapeutics, Inc. | Treatment regimen for hormone-sensitive cancers |
MXPA02003719A (es) * | 1999-10-12 | 2002-08-30 | Cell Therapeutics Inc | Fabricacion de congujados de poliglutamato-agente terapeutico. |
-
2006
- 2006-12-05 TW TW095145182A patent/TWI322010B/zh not_active IP Right Cessation
- 2006-12-05 EP EP06838948A patent/EP1957065A1/en not_active Withdrawn
- 2006-12-05 KR KR1020087015960A patent/KR20080074202A/ko not_active Application Discontinuation
- 2006-12-05 JP JP2008544422A patent/JP2009518406A/ja active Pending
- 2006-12-05 WO PCT/US2006/046281 patent/WO2007067498A1/en active Application Filing
- 2006-12-05 RU RU2008127309/15A patent/RU2008127309A/ru not_active Application Discontinuation
- 2006-12-05 CA CA002630553A patent/CA2630553A1/en not_active Abandoned
- 2006-12-05 PE PE2006001549A patent/PE20070701A1/es not_active Application Discontinuation
- 2006-12-05 US US11/634,356 patent/US20070167349A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TWI322010B (en) | 2010-03-21 |
WO2007067498A1 (en) | 2007-06-14 |
RU2008127309A (ru) | 2010-01-20 |
KR20080074202A (ko) | 2008-08-12 |
JP2009518406A (ja) | 2009-05-07 |
US20070167349A1 (en) | 2007-07-19 |
EP1957065A1 (en) | 2008-08-20 |
TW200803836A (en) | 2008-01-16 |
CA2630553A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Du et al. | Hyaluronic acid-based dissolving microneedle patch loaded with methotrexate for improved treatment of psoriasis | |
MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
CY1119059T1 (el) | Χρηση προφαρμακων κανναβιδιολης σε τοπικη και διαδερμικη χορηγηση με μικροβελονες | |
WO2009105432A3 (en) | Devices and methods for delivery of a therapeutic agent through a pneumostoma | |
AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
DOP2006000057A (es) | Composición farmaceútica para el tratamiento del cáncer | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
WO2010009111A3 (en) | A drug depot implantable within a synovial joint | |
IN2012DN00407A (es) | ||
MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
EP4124346A3 (en) | Compositions and methods for treating diseases | |
CY1123398T1 (el) | Συνθεση συνδυασμου | |
BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
PE20091574A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
BR112022014070A2 (pt) | Nanopartículas de lipídio para dispensar medicamentos in vivo e usos das mesmas | |
WO2014160216A3 (en) | Dual targeting anticancer agents | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
ATE507818T1 (de) | Orale verabreichung eines calcitonins | |
ES2525066T3 (es) | Uso terapéutico de preparaciones farmacéuticas que contienen fármacos antitumorales unidos a ácido hialurónico en el tratamiento de neoplasias | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
PE20070701A1 (es) | Terapia contra el cancer con estrogeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |